{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:30:47Z","timestamp":1785742247255,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T00:00:00Z","timestamp":1539648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00415-018-9083-5","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T11:05:54Z","timestamp":1539687954000},"page":"2980-2992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry"],"prefix":"10.1007","volume":"265","author":[{"name":"NTD Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Braune","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"van H\u00f6vell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Freudensprung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnfin","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,16]]},"reference":[{"key":"9083_CR1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2217\/cer-2016-0085","volume":"6","author":"A Chan","year":"2017","unstructured":"Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res 6:313\u2013323","journal-title":"J Comp Eff Res"},{"issue":"14 suppl","key":"9083_CR2","doi-asserted-by":"crossref","first-page":"P3.243","DOI":"10.1212\/WNL.84.14_supplement.P3.243","volume":"84","author":"R Fox","year":"2015","unstructured":"Fox R, Hutchinson M, Havrdova E, Kurukulasuriya N, Siddiqui K, Sarda S (2015) Systematic review and mixed treatment comparison of delayed-release dimethyl fumarate and other disease-modifying therapies in treatment-na\u00efve patients with relapsing-remitting multiple sclerosis. Neurology 84(14 suppl):P3.243","journal-title":"Neurology"},{"key":"9083_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/03007995.2016.1248380","volume":"33","author":"RJ Fox","year":"2017","unstructured":"Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL (2017) Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin 33:175\u2013183","journal-title":"Curr Med Res Opin"},{"key":"9083_CR4","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, Investigators CS (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087\u20131097","journal-title":"N Engl J Med"},{"key":"9083_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1185\/03007995.2013.863755","volume":"30","author":"M Hutchinson","year":"2014","unstructured":"Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B (2014) Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 30:613\u2013627","journal-title":"Curr Med Res Opin"},{"key":"9083_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.7326\/0003-4819-151-3-200908040-00126","volume":"151","author":"BR Luce","year":"2009","unstructured":"Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS (2009) Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 151:206\u2013209","journal-title":"Ann Intern Med"},{"key":"9083_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","volume":"6","author":"A Boster","year":"2017","unstructured":"Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A (2017) Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol Ther 6:91\u2013102","journal-title":"Neurol Ther"},{"issue":"16 suppl","key":"9083_CR8","doi-asserted-by":"crossref","first-page":"P6.375","DOI":"10.1212\/WNL.88.16_supplement.P6.375","volume":"88","author":"J Nicholas","year":"2017","unstructured":"Nicholas J, Boster A, Wu N, Huang M-Y, Riester K, Jhaveri M, Edwards M, Lee A (2017) Comparative effectiveness of delayed-release dimethyl fumarate versus fingolimod and teriflunomide on risk of relapse. Neurology 88(16 suppl):P6.375","journal-title":"Neurology"},{"key":"9083_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40120-016-0061-5","volume":"6","author":"A Lee","year":"2017","unstructured":"Lee A, Pike J, Edwards MR, Petrillo J, Waller J, Jones E (2017) Quantifying the benefits of dimethyl fumarate over \u03b2 interferon and glatiramer acetate therapies on work productivity outcomes in MS patients. Neurol Ther 6:79\u201390","journal-title":"Neurol Ther"},{"issue":"16 suppl","key":"9083_CR10","doi-asserted-by":"crossref","first-page":"S31.003","DOI":"10.1212\/WNL.88.16_supplement.S31.003","volume":"88","author":"C Hersh","year":"2017","unstructured":"Hersh C, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Fox RJ, Bermel RA, Cohen JA, Ontaneda D (2017) Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Neurology 88(16 suppl):S31.003","journal-title":"Neurology"},{"key":"9083_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.msard.2016.08.002","volume":"10","author":"CM Hersh","year":"2016","unstructured":"Hersh CM, Love TE, Cohn S, Hara-Cleaver C, Bermel RA, Fox RJ, Cohen JA, Ontaneda D (2016) Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Mult Scler Relat Disord 10:44\u201352","journal-title":"Mult Scler Relat Disord"},{"issue":"16 suppl","key":"9083_CR12","doi-asserted-by":"crossref","first-page":"P3.109","DOI":"10.1212\/WNL.86.16_supplement.P3.109","volume":"86","author":"D Ontaneda","year":"2016","unstructured":"Ontaneda D, Vollmer B, Sillau S, Cohn S, Nair K, Bermel R, Vollmer T, Fox R, Corboy J, Cohen J, Hersh C, Alvarez E (2016) Comparative efficacy and discontinuation of fingolimod and dimethyl fumarate in two large academic medical centers. Neurology 86(16 suppl):P3.109","journal-title":"Neurology"},{"issue":"16 suppl","key":"9083_CR13","doi-asserted-by":"crossref","first-page":"P6.381","DOI":"10.1212\/WNL.88.16_supplement.P6.381","volume":"88","author":"N Sattarnezhad","year":"2017","unstructured":"Sattarnezhad N, Healy BC, Baharnoori M, Diaz-Cruz C, Stankiewicz J, Weiner HL, Chitnis T (2017) Dimethyl fumarate versus interferon for treatment of relapsing-remitting multiple sclerosis. Neurology 88(16 suppl):P6.381","journal-title":"Neurology"},{"issue":"16 suppl","key":"9083_CR14","doi-asserted-by":"crossref","first-page":"P6.372","DOI":"10.1212\/WNL.88.16_supplement.P6.372","volume":"88","author":"T Spelman","year":"2017","unstructured":"Spelman T, Kalincik T, Trojana M, Grand-Maison F, Izquierdo G, Havrdova E, Horakova D, Lugaresi A, Duquette P, Grammond P, Hupperts R, Lechner-Scott J, Granella F, Petersen T, Terzi M, Pucci E, Sola P, Van Pesch V, Iuliano G, Boz C, Bergamaschi R, Slee M, Butzkueven H (2017) Comparative analysis of MS outcomes in dimethyl fumarate-treated patients relative to propensity matched fingolimod, interferon, glatiramer acetate, or teriflunomide. Neurology 88(16 suppl):P6.372","journal-title":"Neurology"},{"key":"9083_CR15","first-page":"261","volume":"12","author":"I Ayzenberg","year":"2016","unstructured":"Ayzenberg I, Hoepner R, Kleiter I (2016) Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations. Ther Clin Risk Manag 12:261\u2013272","journal-title":"Ther Clin Risk Manag"},{"key":"9083_CR16","unstructured":"European Medicines Agency. Gilenya [summary of product characteristics]. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/002202\/WC500104528.pdf . Accessed 7 Aug 2017"},{"key":"9083_CR17","unstructured":"Parsons LS (2001) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. SAS Paper 214-26"},{"key":"9083_CR18","unstructured":"Faria R, Hernandez Alava M, Manca A, Wailoo A (2015) NICE DSU Technical Support Document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. http:\/\/scharr.dept.shef.ac.uk\/nicedsu\/wpcontent\/uploads\/sites\/7\/2016\/03\/TSD17-DSU-Observational-data-FINAL.pdf . Accessed 22 Mar 2018"},{"key":"9083_CR19","first-page":"597","volume":"113","author":"O Kuss","year":"2016","unstructured":"Kuss O, Blettner M, Borgermann J (2016) Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int 113:597\u2013603","journal-title":"Dtsch Arztebl Int"},{"key":"9083_CR20","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","volume":"33","author":"JM Franklin","year":"2014","unstructured":"Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S (2014) Metrics for covariate balance in cohort studies of causal effects. Stat Med 33:1685\u20131699","journal-title":"Stat Med"},{"key":"9083_CR21","first-page":"1","volume":"7","author":"[EUnetHTA]. European Network for Health Technology Assessment","year":"2015","unstructured":"[EUnetHTA]. European Network for Health Technology Assessment (2015) Guideline: internal validity of non-randomised studies (NRS) on interventions. EUnetHTA Joint Action 2 WP 7:1\u201333","journal-title":"EUnetHTA Joint Action 2 WP"},{"key":"9083_CR22","first-page":"1","volume":"7","author":"[EUnetHTA]. European Network for Health Technology Assessment","year":"2015","unstructured":"[EUnetHTA]. European Network for Health Technology Assessment (2015) Guideline: levels of evidence\u2014internal validity of randomised controlled trials. EUnetHTA Joint Action 2 WP 7:1\u201333","journal-title":"EUnetHTA Joint Action 2 WP"},{"key":"9083_CR23","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1177\/1352458516653667","volume":"22","author":"T Kalincik","year":"2016","unstructured":"Kalincik T, Butzkueven H (2016) Observational data: Understanding the real MS world. Mult Scler 22:1642\u20131648","journal-title":"Mult Scler"},{"key":"9083_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCOUTCOMES.108.790634","volume":"1","author":"PC Austin","year":"2008","unstructured":"Austin PC (2008) Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes 1:62\u201367","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9083-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9083-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T11:52:17Z","timestamp":1720698737000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9083-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,16]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["9083"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9083-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,16]]},"assertion":[{"value":"8 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SB received honoraria from Kassen\u00e4rztliche Vereinigung Bayerns and health maintenance organisations for patient care, and from Biogen, MedDay, NeuroTransData, Novartis, and Roche for consulting, project management, clinical studies, and lectures; he also received honoraria and expense compensation as a board member of NeuroTransData. SG and PvH are employees of PwC, which was contracted to perform the statistical analysis for NeuroTransData. UF, RH, and FP are employees of and hold stock\/stock options in Biogen. AB received honoraria from NeuroTransData for project management, clinical studies, and travel expenses from Novartis and Servier; he also received honoraria and expense compensation as a board member of NeuroTransData.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain clinical studies or individually identifiable patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}